Evicenter
P&T meetings

SL1009 (sodium dichloroacetate)

Pyruvate dehydrogenase complex deficiency

Manufacturer
Saol Therapeutics
Regulatory submission
NDA resubmitted June 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Pyruvate dehydrogenase complex deficiency

Economic burden and healthcare resource utilization

5 evidence topics · 6 sources

Broader mitochondrial-disease population: Ontario, Canada

“(mean = CAD$24,023 in 12 months before first hospitalization)” (opens the source at this quote in a new tab)

“within the single-payer Ontario health care system.” (opens the source at this quote in a new tab)

Broader mitochondrial disease: U.S. healthcare costs

“Total allowed per member per month (PMPM) cost for pediatric patients was $4829 and $3100 for adults” (opens the source at this quote in a new tab)

Broader mitochondrial disease: treatment costs in China

“The average monthly treatment cost was 3000 RMB for children and 3100 RMB for adults.” (opens the source at this quote in a new tab)

Broader mitochondrial disease review: cost evidence

“No studies reported costs data.” (opens the source at this quote in a new tab)

Patient employment: adult PDCD

“This limits his ability to work” (opens the source at this quote in a new tab)